Erratum: A Phase 2 Multi-center, Open-label, Switch-over Trial to Evaluate the Safety and Efficacy of Abcertin® in Patients with Type 1 Gaucher Disease

Documenti analoghi

• A Phase 2 Multi-center, Open-label, Switch-over Trial to Evaluate the Safety and Efficacy of Abcertin® in Patients with Type 1 Gaucher Disease
  di: Choi, Jin-Ho, et al.
  Pubblicazione: (2015)
• A multicenter, open-label, phase III study of Abcertin in Gaucher disease
  di: Lee, Beom Hee, et al.
  Pubblicazione: (2017)
• The GBA p.G85E mutation in Korean patients with non-neuronopathic Gaucher disease: founder and neuroprotective effects
  di: Kim, Yoo-Mi, et al.
  Pubblicazione: (2020)
• A multicenter, open-label, phase III study of Abcertin in Gaucher disease: Erratum
  Pubblicazione: (2018)
• Clinical and genetic characteristics of Gaucher disease according to phenotypic subgroups
  di: Lee, Ju-Young, et al.
  Pubblicazione: (2012)